NCT06565650View on ClinicalTrials.gov

A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.

PHASE4Active, not recruitingINTERVENTIONAL

Enrollment

216

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions

Dry Eye

Interventions

DRUG

Miebo

100% perfluorohexyloctane

DRUG

Saline

0.6% sodium chloride solution

Trial Locations (12)

28803

Site 108, Asheville

30260

Site 107, Morrow

33484

Site 113, Delray Beach

38119

Site 103, Memphis

46290

Site 105, Carmel

63131

Site 104, St Louis

64111

Site 110, Kansas City

90505

Site 106, Torrance

91204

Site 101, Glendale

92562

Site 112, Murrieta

92663

Site 102, Newport Beach

95670

Site 109, Rancho Cordova

All Listed Sponsors

lead

Bausch & Lomb Incorporated

INDUSTRY

NCT06565650 - A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months. | Biotech Hunter | Biotech Hunter